Subgroup analyses.
obesity, comorbidity
OBESITY, SECONDARY
Subgroup analyses of the primary outcomes of symptomatic (upper panel) and severe (lower panel) COVID-19 are shown using Forest plots of the difference in percent and 95% confidence intervals, adjusted for stratification factors used in randomisation. Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.Participant characteristics.Note: Results are number and % with available data unless otherwise stated. Denominators differ for obesity due to missing data1967194116721683. Denominators differ as baseline swabs taken in Brazil only12851283.Primary and secondary outcomes.Numbers in parentheses represent 95% confidence intervals where not otherwise specified.Confidence interval widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing.aHR: adjusted hazard ratio Adjusted for stratification factors used at randomisation (age, geographical location, presence of comorbidity).For 3 or more consecutive days.Within participant with symptomatic and/or severe COVID-19, reported as median (interquartile range).Reported as median (interquartile range).The number of days with symptoms is presented by age group and presence of comorbidities, due to a significant interaction between treatment arm and age group and presence of comorbidities which rendered the main arm comparison non-interpretable.Denominators are: <40 years-old subgroup: 740 BCG, 734 placebo; 40 to 59 years-old subgroup: 811 BCG, 802 placebo; ≥60 years-old subgroup: 152 BCG, 147 placebo; presence of comorbidity subgroup: 356 BCG, 333 placebo; absence of comorbidity subgroup: 1347 BCG, 1350 placebo.